Pre-market drop of more than 8%! Test results of Pfizer's competitor Vutrisiran under ALNY.US are not statistically significant

The Zhitong Finance App learned that the stock price of Aliram Pharmaceuticals (ALNY.US) fell more than 8% in pre-market trading on Friday because the company announced the full results of its post-trial trial of the heart disease drug vutrisiran. The results showed that in the monotherapy group, the risk of death was relatively reduced by 30% compared to placebo, but this reduction was not statistically significant. Furthermore, the drug is thought to be likely to compete with Pfizer's (PFE.US) blockbuster treatment, tafamidis.

According to information, Vutrisiran uses RNA interference therapy and targets transthyroxine amyloid cardiomyopathy (ATTR-CM), a disease caused by abnormal accumulation of misfolded transthyroxine protein in the body.

In addition to the monotherapy group, the study included patients receiving standard treatments (such as tafamidis and SGLT2 inhibitors) at the same time. Detailed data revealed at the European medical event on Friday showed that vutrisiran was able to reduce all-cause mortality and the main composite index of recurrent cardiovascular events by 28%. During the 33-36 month double-blind period and up to 42 months, vutrisiran reduced the incidence rate by 31% and 36%, respectively.

Aliram Pharmaceuticals emphasizes that the safety and tolerability of vutrisiran is consistent with previous trial data and the results of currently approved patient groups. The results of the HELIOS-B study have been published in the New England Journal of Medicine. The company plans to begin submitting vutrisiran's listing applications to global regulators later this year.

Aliram Pharmaceuticals has marketed Vutrisiran under the amvuttra brand to treat polyneuropathy in adults, and is undergoing phase 3 trials of HELIOS-B to expand its indications to ATTR amyloidosis associated with cardiomyopathy. Meanwhile, BridgeBio's (BBIO.US) ATTR-CM remedy Acoramidis is currently undergoing priority review by the US Food and Drug Administration (FDA). Affected by this news, BridgeBio's stock price has risen by about 16%, while Pfizer's stock price has also risen slightly.

It is worth mentioning that Ariram Pharmaceuticals released preliminary data from the HELIOS-B trial in June, showing that the global multi-center study reached the main and secondary endpoints, reducing all-cause mortality and comprehensive indicators of recurrent cardiovascular events by 28% and 33%, respectively.